Clinical trial
A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate (Glivec®) Plasmatic Through Level in Patients Newly Diagnosed With Chronic Phase Chronic Myelogenous Leukaemia (CP-CML).
NCT02896842 is registered in ClinicalTrials.gov with Versailles Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate (Glivec®) Plasmatic Through Level in Patients Newly Diagnosed With Chronic Phase Chronic Myelogenous Leukaemia (CP-CML).
- Lead sponsor
- Versailles Hospital
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2010
- Completion date
- December 31, 2016
- Enrollment
- 139 (actual)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.